Clinical Trial Update: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 trial evaluating a personalized monotherapy regimen of brolucizumab for macular polypoidal choroidal vasculopath…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Polypoidal Choroidal Vasculopathy

Drugs mentioned

• BEOVU (BROLUCIZUMAB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Status: COMPLETED